Clinical Trial Update: Clinical Utility of Subcutaneous Furosemide in Patients Presenting With Early Signs of Fluid Overload [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial evaluating subcutaneous furosemide for early fluid overload in heart failure was terminated; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure

Drugs mentioned

• Subcutaneous furosemide (furosemide)

Snippet

Sponsor: Steward St. Elizabeth's Medical Center of Boston, Inc. | Conditions: Heart Failure | Phase 2, Phase 3 | Status: TERMINATED | Results posted: 2022-10-13